Skip to main content
Top
Published in: Trials 1/2012

Open Access 01-12-2012 | Review

Adaptive trial designs: a review of barriers and opportunities

Authors: John A Kairalla, Christopher S Coffey, Mitchell A Thomann, Keith E Muller

Published in: Trials | Issue 1/2012

Login to get access

Abstract

Adaptive designs allow planned modifications based on data accumulating within a study. The promise of greater flexibility and efficiency stimulates increasing interest in adaptive designs from clinical, academic, and regulatory parties. When adaptive designs are used properly, efficiencies can include a smaller sample size, a more efficient treatment development process, and an increased chance of correctly answering the clinical question of interest. However, improper adaptations can lead to biased studies. A broad definition of adaptive designs allows for countless variations, which creates confusion as to the statistical validity and practical feasibility of many designs. Determining properties of a particular adaptive design requires careful consideration of the scientific context and statistical assumptions. We first review several adaptive designs that garner the most current interest. We focus on the design principles and research issues that lead to particular designs being appealing or unappealing in particular applications. We separately discuss exploratory and confirmatory stage designs in order to account for the differences in regulatory concerns. We include adaptive seamless designs, which combine stages in a unified approach. We also highlight a number of applied areas, such as comparative effectiveness research, that would benefit from the use of adaptive designs. Finally, we describe a number of current barriers and provide initial suggestions for overcoming them in order to promote wider use of appropriate adaptive designs. Given the breadth of the coverage all mathematical and most implementation details are omitted for the sake of brevity. However, the interested reader will find that we provide current references to focused reviews and original theoretical sources which lead to details of the current state of the art in theory and practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chow S, Chang M: Adaptive design methods in clinical trials. 2007, Boca Raton: Chapman & Hall/CRC Chow S, Chang M: Adaptive design methods in clinical trials. 2007, Boca Raton: Chapman & Hall/CRC
2.
go back to reference Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J: Adaptive designs in clinical drug development: an executive summary of the PhRMA working group. J Biopharm Stat. 2006, 16: 275-283. 10.1080/10543400600614742.CrossRefPubMed Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J: Adaptive designs in clinical drug development: an executive summary of the PhRMA working group. J Biopharm Stat. 2006, 16: 275-283. 10.1080/10543400600614742.CrossRefPubMed
4.
go back to reference Coffey CS, Kairalla JA: Adaptive clinical trials: progress and challenges. Drugs R&D. 2008, 9: 229-242. 10.2165/00126839-200809040-00003.CrossRef Coffey CS, Kairalla JA: Adaptive clinical trials: progress and challenges. Drugs R&D. 2008, 9: 229-242. 10.2165/00126839-200809040-00003.CrossRef
5.
go back to reference Chow SC, Corey R: Benefits, challenges and obstacles of adaptive clinical trial designs. Orph J Rare Dis. 2011, 6: 79-10.1186/1750-1172-6-79.CrossRef Chow SC, Corey R: Benefits, challenges and obstacles of adaptive clinical trial designs. Orph J Rare Dis. 2011, 6: 79-10.1186/1750-1172-6-79.CrossRef
6.
go back to reference Bretz F, Koenig F, Brannath W, Glimm E, Posch M: Adaptive designs for confirmatory clinical trials. Stat Med. 2009, 28: 1181-1217. 10.1002/sim.3538.CrossRefPubMed Bretz F, Koenig F, Brannath W, Glimm E, Posch M: Adaptive designs for confirmatory clinical trials. Stat Med. 2009, 28: 1181-1217. 10.1002/sim.3538.CrossRefPubMed
7.
go back to reference Emerson SS, Fleming TR: Adaptive Methods: Telling “The Rest of the Story”. J Biopharm Stat. 2010, 20: 1150-1165. 10.1080/10543406.2010.514457.CrossRefPubMed Emerson SS, Fleming TR: Adaptive Methods: Telling “The Rest of the Story”. J Biopharm Stat. 2010, 20: 1150-1165. 10.1080/10543406.2010.514457.CrossRefPubMed
8.
go back to reference Coffey CS: Adaptive Design Across Stages of Therapeutic Development. Clinical Trials in Neurology: Design, Conduct, & Analysis. Edited by: Ravina B, Cummings J, McDermott M, Poole RM. 2012, Cambridge: Cambridge University Press, 91-100.CrossRef Coffey CS: Adaptive Design Across Stages of Therapeutic Development. Clinical Trials in Neurology: Design, Conduct, & Analysis. Edited by: Ravina B, Cummings J, McDermott M, Poole RM. 2012, Cambridge: Cambridge University Press, 91-100.CrossRef
9.
go back to reference Brannath W, Koenig F, Bauer P: Multiplicity and flexibility in clinical trials. Pharm Stat. 2007, 6: 205-216. 10.1002/pst.302.CrossRefPubMed Brannath W, Koenig F, Bauer P: Multiplicity and flexibility in clinical trials. Pharm Stat. 2007, 6: 205-216. 10.1002/pst.302.CrossRefPubMed
10.
go back to reference Dragalin V: Adaptive designs: terminology and classification. Drug Inf J. 2006, 40: 425-435. Dragalin V: Adaptive designs: terminology and classification. Drug Inf J. 2006, 40: 425-435.
11.
go back to reference Burton A, Altman DG, Royston P, Holder RL: The design of simulation studies in medical statistics. Stat Med. 2006, 24: 4279-4292.CrossRef Burton A, Altman DG, Royston P, Holder RL: The design of simulation studies in medical statistics. Stat Med. 2006, 24: 4279-4292.CrossRef
12.
go back to reference Storer BE: Design and Analysis of Phase I Clinical Trials. Biometrics. 1989, 45: 925-937. 10.2307/2531693.CrossRefPubMed Storer BE: Design and Analysis of Phase I Clinical Trials. Biometrics. 1989, 45: 925-937. 10.2307/2531693.CrossRefPubMed
13.
go back to reference Tourneau CL, Lee JJ, Siu LL: Dose Escalation Methods in Phase I Cancer Clinical Trials. J Natl Cancer I. 2009, 101: 708-720. 10.1093/jnci/djp079.CrossRef Tourneau CL, Lee JJ, Siu LL: Dose Escalation Methods in Phase I Cancer Clinical Trials. J Natl Cancer I. 2009, 101: 708-720. 10.1093/jnci/djp079.CrossRef
14.
go back to reference O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990, 46: 33-48. 10.2307/2531628.CrossRefPubMed O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990, 46: 33-48. 10.2307/2531628.CrossRefPubMed
15.
go back to reference Cheung K, Kaufmann P: Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke. 2011, 42: 2990-2994. 10.1161/STROKEAHA.111.620765.CrossRefPubMedPubMedCentral Cheung K, Kaufmann P: Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke. 2011, 42: 2990-2994. 10.1161/STROKEAHA.111.620765.CrossRefPubMedPubMedCentral
16.
go back to reference Garrett-Mayer E: The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006, 3: 57-71. 10.1191/1740774506cn134oa.CrossRefPubMed Garrett-Mayer E: The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006, 3: 57-71. 10.1191/1740774506cn134oa.CrossRefPubMed
17.
go back to reference Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G: Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2011, 30: 1039-1045.CrossRefPubMedPubMedCentral Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G: Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2011, 30: 1039-1045.CrossRefPubMedPubMedCentral
18.
go back to reference Elkind MSV, Sacco RL, MacArthur RB, Peerschke E, Neils G, Andrews H, Stillman J, Corporan T, Leifer D, Liu R, Cheung K: High-dose Lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis. 2009, 28: 266-275. 10.1159/000228709.CrossRefPubMedPubMedCentral Elkind MSV, Sacco RL, MacArthur RB, Peerschke E, Neils G, Andrews H, Stillman J, Corporan T, Leifer D, Liu R, Cheung K: High-dose Lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis. 2009, 28: 266-275. 10.1159/000228709.CrossRefPubMedPubMedCentral
19.
go back to reference Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y: Safety and tolerability of Deferoxamine Mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011, 42: 3067-3074. 10.1161/STROKEAHA.111.617589.CrossRefPubMedPubMedCentral Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y: Safety and tolerability of Deferoxamine Mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011, 42: 3067-3074. 10.1161/STROKEAHA.111.617589.CrossRefPubMedPubMedCentral
20.
go back to reference Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu C, Konig F, Krams M, Liu Q, Neuenschwander B, Parke T, Pinheiro J, Roy A, Sax R, Shen F: Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007, 17: 965-995. 10.1080/10543400701643848.CrossRefPubMed Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu C, Konig F, Krams M, Liu Q, Neuenschwander B, Parke T, Pinheiro J, Roy A, Sax R, Shen F: Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007, 17: 965-995. 10.1080/10543400701643848.CrossRefPubMed
21.
go back to reference Berry DA, Mueller P, Grieve AP, Smith M: Bayesian designs for dose-ranging drug trials. Case studies in Bayesian statistics, Vol. 5. Edited by: Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M. 2002, New York: Springer, 99-181. Berry DA, Mueller P, Grieve AP, Smith M: Bayesian designs for dose-ranging drug trials. Case studies in Bayesian statistics, Vol. 5. Edited by: Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M. 2002, New York: Springer, 99-181.
22.
go back to reference Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J, Ford GA: ASTIN: an adaptive dose -response study of UK-279,276 in acute ischemic stroke. Stroke. 2003, 34: 2543-2549. 10.1161/01.STR.0000092527.33910.89.CrossRefPubMed Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J, Ford GA: ASTIN: an adaptive dose -response study of UK-279,276 in acute ischemic stroke. Stroke. 2003, 34: 2543-2549. 10.1161/01.STR.0000092527.33910.89.CrossRefPubMed
23.
go back to reference Jennison C, Turnbull BW: Group Sequential Methods. 2000, Boca Raton: Chapman & Hall/CRC Jennison C, Turnbull BW: Group Sequential Methods. 2000, Boca Raton: Chapman & Hall/CRC
24.
go back to reference Zhang L, Rosenburger W: Adaptive randomization in clinical trials. Design and Analysis of Experiments, Special Designs and Applications. Volume 3. Edited by: Hinkelmann K. 2012, Hoboken: John Wiley & Sons, 251-282.CrossRef Zhang L, Rosenburger W: Adaptive randomization in clinical trials. Design and Analysis of Experiments, Special Designs and Applications. Volume 3. Edited by: Hinkelmann K. 2012, Hoboken: John Wiley & Sons, 251-282.CrossRef
25.
go back to reference Rosenberger WF, Sverdlov O, Hu F: Adaptive Randomization for Clinical Trials. J Biopharm Stat. 2012, 22: 719-736. 10.1080/10543406.2012.676535.CrossRefPubMed Rosenberger WF, Sverdlov O, Hu F: Adaptive Randomization for Clinical Trials. J Biopharm Stat. 2012, 22: 719-736. 10.1080/10543406.2012.676535.CrossRefPubMed
26.
go back to reference Rosenberger WF, Sverdlov O: Handling covariates in the design of clinical trials. Stat Sci. 2008, 23: 404-419. 10.1214/08-STS269.CrossRef Rosenberger WF, Sverdlov O: Handling covariates in the design of clinical trials. Stat Sci. 2008, 23: 404-419. 10.1214/08-STS269.CrossRef
27.
go back to reference Antognini AB, Zagoraiou M: The covariate-adaptive biased coin design for balancing clinical trials in the presence of prognostic factors. Biometrika. 2011, 98: 519-535. 10.1093/biomet/asr021.CrossRef Antognini AB, Zagoraiou M: The covariate-adaptive biased coin design for balancing clinical trials in the presence of prognostic factors. Biometrika. 2011, 98: 519-535. 10.1093/biomet/asr021.CrossRef
28.
go back to reference Jensen RK, Leboeuf-Yde C, Wedderkopp N, Sorensen JS, Minniche C: Rest versus exercise as treatment for patients with low back pain and Modic changes. A randomized controlled trial. BMC Med. 2012, 10: 22-35. 10.1186/1741-7015-10-22.CrossRefPubMedPubMedCentral Jensen RK, Leboeuf-Yde C, Wedderkopp N, Sorensen JS, Minniche C: Rest versus exercise as treatment for patients with low back pain and Modic changes. A randomized controlled trial. BMC Med. 2012, 10: 22-35. 10.1186/1741-7015-10-22.CrossRefPubMedPubMedCentral
29.
go back to reference Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB: Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985, 76: 479-487.PubMed Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB: Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985, 76: 479-487.PubMed
30.
go back to reference Eitner F, Ackermann D, Hilgers RD, Floege J: Supportive versus immunosuppressive therapy of progressive IgA Nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol. 2008, 21: 284-289.PubMed Eitner F, Ackermann D, Hilgers RD, Floege J: Supportive versus immunosuppressive therapy of progressive IgA Nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol. 2008, 21: 284-289.PubMed
31.
go back to reference Fiore LD, Brophy M, Ferguson RE, D’Avolio L, Hermos JA, Lew RA, Doros G, Conrad CH, O’Neil JA, Sabin TP, Kaufman J, Swartz SL, Lawler E, Liang MH, Gaziano JM, Lavori PW: A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials. 2011, 8: 183-195. 10.1177/1740774511398368.CrossRefPubMedPubMedCentral Fiore LD, Brophy M, Ferguson RE, D’Avolio L, Hermos JA, Lew RA, Doros G, Conrad CH, O’Neil JA, Sabin TP, Kaufman J, Swartz SL, Lawler E, Liang MH, Gaziano JM, Lavori PW: A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials. 2011, 8: 183-195. 10.1177/1740774511398368.CrossRefPubMedPubMedCentral
32.
go back to reference Yuan Y, Huang X, Liu S: A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011, 30: 1218-1229. 10.1002/sim.4218.CrossRefPubMedPubMedCentral Yuan Y, Huang X, Liu S: A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011, 30: 1218-1229. 10.1002/sim.4218.CrossRefPubMedPubMedCentral
33.
go back to reference Fardipour P, Littman G, Burns DD, Dragalin V, Padmanabhan SK, Parke T, Perevozskaya I, Reinold K, Sharma A, Krams M: Planning and executing response-adaptive learn-phase clinical trials: 1. The process. Drug Inf J. 2009, 43: 713-723. 10.1177/009286150904300609.CrossRef Fardipour P, Littman G, Burns DD, Dragalin V, Padmanabhan SK, Parke T, Perevozskaya I, Reinold K, Sharma A, Krams M: Planning and executing response-adaptive learn-phase clinical trials: 1. The process. Drug Inf J. 2009, 43: 713-723. 10.1177/009286150904300609.CrossRef
34.
go back to reference Gu X, Lee JJ: A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol. 2010, 10: 48-62. 10.1186/1471-2288-10-48.CrossRefPubMedPubMedCentral Gu X, Lee JJ: A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol. 2010, 10: 48-62. 10.1186/1471-2288-10-48.CrossRefPubMedPubMedCentral
35.
go back to reference Wang SJ: The bias issue under the complete null with response adaptive randomization: Commentary on “Adaptive and model-based dose-ranging trials: Quantitative evaluation and recommendation”. Stat Biopharm Res. 2012, 2: 458-461.CrossRef Wang SJ: The bias issue under the complete null with response adaptive randomization: Commentary on “Adaptive and model-based dose-ranging trials: Quantitative evaluation and recommendation”. Stat Biopharm Res. 2012, 2: 458-461.CrossRef
36.
go back to reference Korn EL, Freidlin B: Outcome-adaptive randomization: is it useful?. J Clin Oncol. 2011, 29: 771-776.CrossRefPubMed Korn EL, Freidlin B: Outcome-adaptive randomization: is it useful?. J Clin Oncol. 2011, 29: 771-776.CrossRefPubMed
37.
go back to reference Temple R: Enrichment of clinical study populations. Clin Pharmacol Ther. 2010, 88: 774-778. 10.1038/clpt.2010.233.CrossRefPubMed Temple R: Enrichment of clinical study populations. Clin Pharmacol Ther. 2010, 88: 774-778. 10.1038/clpt.2010.233.CrossRefPubMed
38.
go back to reference Freidlin B, Simon R: Evaluation of randomized discontinuation design. J Clin Oncol. 2005, 23: 5094-5098. 10.1200/JCO.2005.02.520.CrossRefPubMed Freidlin B, Simon R: Evaluation of randomized discontinuation design. J Clin Oncol. 2005, 23: 5094-5098. 10.1200/JCO.2005.02.520.CrossRefPubMed
39.
go back to reference Wang SJ, Hung HMJ, O’Neill RT: Adaptive patient enrichment designs in therapeutic trials. Biometrical J. 2009, 51: 358-374. 10.1002/bimj.200900003.CrossRef Wang SJ, Hung HMJ, O’Neill RT: Adaptive patient enrichment designs in therapeutic trials. Biometrical J. 2009, 51: 358-374. 10.1002/bimj.200900003.CrossRef
40.
go back to reference Van der Baan FH, Knol MJ, Klungel OH, Egberts ACG, Grobbee DE, Roes KCB: Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics. 2012, 13: 571-578. 10.2217/pgs.12.10.CrossRefPubMed Van der Baan FH, Knol MJ, Klungel OH, Egberts ACG, Grobbee DE, Roes KCB: Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics. 2012, 13: 571-578. 10.2217/pgs.12.10.CrossRefPubMed
41.
go back to reference Ho TW, Pearlman E, Lewis D, Hamalainen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ: Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012, 32: 760-765.CrossRef Ho TW, Pearlman E, Lewis D, Hamalainen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ: Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012, 32: 760-765.CrossRef
42.
go back to reference Proschan MA: Sample size re-estimation in clinical trials. Biometrical J. 2009, 51: 348-357. 10.1002/bimj.200800266.CrossRef Proschan MA: Sample size re-estimation in clinical trials. Biometrical J. 2009, 51: 348-357. 10.1002/bimj.200800266.CrossRef
43.
go back to reference Cui L, Hung HMJ, Wang S: Modification of sample size in group sequential clinical trials. Biometrics. 1999, 55: 853-857. 10.1111/j.0006-341X.1999.00853.x.CrossRefPubMed Cui L, Hung HMJ, Wang S: Modification of sample size in group sequential clinical trials. Biometrics. 1999, 55: 853-857. 10.1111/j.0006-341X.1999.00853.x.CrossRefPubMed
44.
go back to reference Tsiatis AA, Mehta C: On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika. 2003, 90: 367-378. 10.1093/biomet/90.2.367.CrossRef Tsiatis AA, Mehta C: On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika. 2003, 90: 367-378. 10.1093/biomet/90.2.367.CrossRef
45.
go back to reference Jennison C, Turnbull BW: Adaptive and nonadaptive group sequential tests. Stat Med. 2006, 25: 917-932. 10.1002/sim.2251.CrossRefPubMed Jennison C, Turnbull BW: Adaptive and nonadaptive group sequential tests. Stat Med. 2006, 25: 917-932. 10.1002/sim.2251.CrossRefPubMed
46.
go back to reference Mehta C, Pocock SJ: Adaptive increase in sample size when interim results are promising: A practical guide with examples. Stat Med. 2011, 30: 3267-3284. 10.1002/sim.4102.CrossRefPubMed Mehta C, Pocock SJ: Adaptive increase in sample size when interim results are promising: A practical guide with examples. Stat Med. 2011, 30: 3267-3284. 10.1002/sim.4102.CrossRefPubMed
47.
go back to reference Wittes J, Brittain E: The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990, 9: 65-72. 10.1002/sim.4780090113.CrossRefPubMed Wittes J, Brittain E: The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990, 9: 65-72. 10.1002/sim.4780090113.CrossRefPubMed
48.
go back to reference Proschan MA: Two-stage sample size re-estimation based on a nuisance parameter: a review. J Biopharm Stat. 2005, 15: 559-574. 10.1081/BIP-200062852.CrossRefPubMed Proschan MA: Two-stage sample size re-estimation based on a nuisance parameter: a review. J Biopharm Stat. 2005, 15: 559-574. 10.1081/BIP-200062852.CrossRefPubMed
49.
go back to reference Friede T, Kieser M: Sample size recalculation in internal pilot study designs: a review. Biometrical J. 2006, 4: 537-555.CrossRef Friede T, Kieser M: Sample size recalculation in internal pilot study designs: a review. Biometrical J. 2006, 4: 537-555.CrossRef
50.
go back to reference Kieser M, Friede T: Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med. 2000, 19: 901-911. 10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L.CrossRefPubMed Kieser M, Friede T: Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med. 2000, 19: 901-911. 10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L.CrossRefPubMed
51.
go back to reference Coffey CS, Muller KE: Controlling test size while gaining the benefits of an internal pilot design. Biometrics. 2001, 57: 625-631. 10.1111/j.0006-341X.2001.00625.x.CrossRefPubMed Coffey CS, Muller KE: Controlling test size while gaining the benefits of an internal pilot design. Biometrics. 2001, 57: 625-631. 10.1111/j.0006-341X.2001.00625.x.CrossRefPubMed
52.
go back to reference Coffey CS, Kairalla JA, Muller KE: Practical methods for bounding type I error rate with an internal pilot design. Comm Stat Theory Methods. 2007, 36: 2143-2157. 10.1080/03610920601143634.CrossRef Coffey CS, Kairalla JA, Muller KE: Practical methods for bounding type I error rate with an internal pilot design. Comm Stat Theory Methods. 2007, 36: 2143-2157. 10.1080/03610920601143634.CrossRef
53.
go back to reference Gould AL, Shih W: Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat Theory Methods. 1992, 21: 2833-2853. 10.1080/03610929208830947.CrossRef Gould AL, Shih W: Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat Theory Methods. 1992, 21: 2833-2853. 10.1080/03610929208830947.CrossRef
54.
go back to reference Friede T, Kieser M: Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Pharm Stat. 2011, 10: 8-13. 10.1002/pst.398.CrossRefPubMed Friede T, Kieser M: Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Pharm Stat. 2011, 10: 8-13. 10.1002/pst.398.CrossRefPubMed
55.
go back to reference Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M: Adaptive seamless phase II/III designs: background operational aspects and examples. Drug Inf J. 2006, 40: 463-473. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M: Adaptive seamless phase II/III designs: background operational aspects and examples. Drug Inf J. 2006, 40: 463-473.
56.
57.
58.
go back to reference Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul J, Gourgou-Bourgade S, Fouchardiere C, Bennouna J, Bachet J, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel R, Montot-Grillot C, Ducreux M: FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364: 1817-1825. 10.1056/NEJMoa1011923.CrossRefPubMed Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul J, Gourgou-Bourgade S, Fouchardiere C, Bennouna J, Bachet J, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel R, Montot-Grillot C, Ducreux M: FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364: 1817-1825. 10.1056/NEJMoa1011923.CrossRefPubMed
59.
go back to reference Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B: Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009, 66: 235-244. 10.1002/ana.21743.CrossRefPubMedPubMedCentral Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B: Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009, 66: 235-244. 10.1002/ana.21743.CrossRefPubMedPubMedCentral
60.
go back to reference Levin B: Selection and Futility Designs. Clinical Trials in Neurology: Design, Conduct, & Analysis. Edited by: Ravina B, Cummings J, McDermott M, Poole RM. 2012, Cambridge: Cambridge University Press, 78-90.CrossRef Levin B: Selection and Futility Designs. Clinical Trials in Neurology: Design, Conduct, & Analysis. Edited by: Ravina B, Cummings J, McDermott M, Poole RM. 2012, Cambridge: Cambridge University Press, 78-90.CrossRef
61.
go back to reference Ravina B, Palesch Y: The phase II futility clinical trial design. Prog Neurother Neuropsych. 2007, 2: 27-38. Ravina B, Palesch Y: The phase II futility clinical trial design. Prog Neurother Neuropsych. 2007, 2: 27-38.
62.
go back to reference Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JLP: A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006, 66: 660-663. 10.1212/01.wnl.0000201182.60750.66.CrossRefPubMed Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JLP: A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006, 66: 660-663. 10.1212/01.wnl.0000201182.60750.66.CrossRefPubMed
63.
go back to reference Tsiatis AA: Information based monitoring of clinical trials. Stat Med. 2006, 25: 3236-3244. 10.1002/sim.2625.CrossRefPubMed Tsiatis AA: Information based monitoring of clinical trials. Stat Med. 2006, 25: 3236-3244. 10.1002/sim.2625.CrossRefPubMed
64.
go back to reference Kairalla JA, Muller KE, Coffey CS: Combining an internal pilot with an interim analysis for single degree of freedom tests. Comm Stat Theory Methods. 2010, 39: 3717-3738. 10.1080/03610920903353709.CrossRef Kairalla JA, Muller KE, Coffey CS: Combining an internal pilot with an interim analysis for single degree of freedom tests. Comm Stat Theory Methods. 2010, 39: 3717-3738. 10.1080/03610920903353709.CrossRef
65.
go back to reference Kairalla JA, Coffey CS, Muller KE: Achieving the benefits of both an internal pilot and interim analysis in large and small samples. JSM Proceedings. 2010, 5239-5252. Kairalla JA, Coffey CS, Muller KE: Achieving the benefits of both an internal pilot and interim analysis in large and small samples. JSM Proceedings. 2010, 5239-5252.
66.
go back to reference Tunis SR, Benner J, McClellan M: Comparative effectiveness research: Policy context, methods development and research infrastructure. Stat Med. 2010, 29: 1963-1976. 10.1002/sim.3818.CrossRefPubMed Tunis SR, Benner J, McClellan M: Comparative effectiveness research: Policy context, methods development and research infrastructure. Stat Med. 2010, 29: 1963-1976. 10.1002/sim.3818.CrossRefPubMed
67.
go back to reference Gurka MJ, Coffey CS, Gurka KK: Internal pilots for observational studies. Biometrical J. 2010, 5: 590-603.CrossRef Gurka MJ, Coffey CS, Gurka KK: Internal pilots for observational studies. Biometrical J. 2010, 5: 590-603.CrossRef
71.
go back to reference The Lancet Neurology: NeuroNEXT: accelerating drug development in neurology. Lancet Neurol. 2012, 11: 119-10.1016/S1474-4422(12)70008-X.CrossRefPubMed The Lancet Neurology: NeuroNEXT: accelerating drug development in neurology. Lancet Neurol. 2012, 11: 119-10.1016/S1474-4422(12)70008-X.CrossRefPubMed
72.
go back to reference Vandemeulebroeke M: Group sequential and adaptive designs-a review of basic concepts and points of discussion. Biometrical J. 2008, 50: 541-557. 10.1002/bimj.200710436.CrossRef Vandemeulebroeke M: Group sequential and adaptive designs-a review of basic concepts and points of discussion. Biometrical J. 2008, 50: 541-557. 10.1002/bimj.200710436.CrossRef
Metadata
Title
Adaptive trial designs: a review of barriers and opportunities
Authors
John A Kairalla
Christopher S Coffey
Mitchell A Thomann
Keith E Muller
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Trials / Issue 1/2012
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-13-145

Other articles of this Issue 1/2012

Trials 1/2012 Go to the issue